140 related articles for article (PubMed ID: 31761652)
1. Selection of Blood, Blood Components, and Blood Products as Essential Medicines in 105 Low- and Middle-Income Countries.
Samukange WT; Gardarsdottir H; Leufkens HGM; Mantel-Teeuwisse AK
Transfus Med Rev; 2020 Apr; 34(2):94-100. PubMed ID: 31761652
[TBL] [Abstract][Full Text] [Related]
2. Comparison of antibiotics included in national essential medicines lists of 138 countries using the WHO Access, Watch, Reserve (AWaRe) classification: a cross-sectional study.
Adekoya I; Maraj D; Steiner L; Yaphe H; Moja L; Magrini N; Cooke G; Loeb M; Persaud N
Lancet Infect Dis; 2021 Oct; 21(10):1429-1440. PubMed ID: 34332706
[TBL] [Abstract][Full Text] [Related]
3. Essential medicines for breast cancer in low and middle income countries.
Bazargani YT; de Boer A; Schellens JH; Leufkens HG; Mantel-Teeuwisse AK
BMC Cancer; 2015 Aug; 15():591. PubMed ID: 26283654
[TBL] [Abstract][Full Text] [Related]
4. A quantitative comparison of essential cardiovascular medicines from countries in the Southern African Development Community to the WHO model essential medicines list.
Naicker I; Suleman F; Perumal-Pillay VA
J Pharm Policy Pract; 2022 Dec; 15(1):97. PubMed ID: 36482421
[TBL] [Abstract][Full Text] [Related]
5. Selection of essential medicines for diabetes in low and middle income countries: a survey of 32 national essential medicines lists.
Bazargani YT; de Boer A; Leufkens HG; Mantel-Teeuwisse AK
PLoS One; 2014; 9(9):e106072. PubMed ID: 25259517
[TBL] [Abstract][Full Text] [Related]
6. Selection of essential medicines for the prevention and treatment of cardiovascular diseases in low and middle income countries.
Bazargani YT; Ugurlu M; de Boer A; Leufkens HGM; Mantel-Teeuwisse AK
BMC Cardiovasc Disord; 2018 Jun; 18(1):126. PubMed ID: 29940880
[TBL] [Abstract][Full Text] [Related]
7. A comparison of national essential medicines lists in the Americas.
Steiner L; Maraj D; Woods H; Jarvis J; Yaphe H; Adekoya I; Bali A; Persaud N
Rev Panam Salud Publica; 2020; 44():e5. PubMed ID: 31998375
[TBL] [Abstract][Full Text] [Related]
8. Essential medicines availability is still suboptimal in many countries: a scoping review.
Mahmić-Kaknjo M; Jeličić-Kadić A; Utrobičić A; Chan K; Bero L; Marušić A
J Clin Epidemiol; 2018 Jun; 98():41-52. PubMed ID: 29452222
[TBL] [Abstract][Full Text] [Related]
9. Selection of oncology medicines in low- and middle-income countries.
Bazargani YT; de Boer A; Schellens JH; Leufkens HG; Mantel-Teeuwisse AK
Ann Oncol; 2014 Jan; 25(1):270-6. PubMed ID: 24356638
[TBL] [Abstract][Full Text] [Related]
10. Essential diabetes medicines and health outcomes in 127 countries.
Budhram D; Benipal S; Bilimoria K; Maraj D; Wang R; Persaud N
Diabetes Obes Metab; 2021 May; 23(5):1121-1128. PubMed ID: 33417268
[TBL] [Abstract][Full Text] [Related]
11. Prices of antihypertensive medicines in sub-Saharan Africa and alignment to WHO's model list of essential medicines.
Twagirumukiza M; Annemans L; Kips JG; Bienvenu E; Van Bortel LM
Trop Med Int Health; 2010 Mar; 15(3):350-61. PubMed ID: 20070634
[TBL] [Abstract][Full Text] [Related]
12. Access to Cytotoxic Medicines by Children With Cancer: A Focus on Low and Middle Income Countries.
Barr R; Robertson J
Pediatr Blood Cancer; 2016 Feb; 63(2):287-91. PubMed ID: 26375626
[TBL] [Abstract][Full Text] [Related]
13. Assessing variation among the national essential medicines lists of 21 high-income countries: a cross-sectional study.
Taglione MS; Persaud N
BMJ Open; 2021 Aug; 11(8):e045262. PubMed ID: 34380717
[TBL] [Abstract][Full Text] [Related]
14. The role of government agencies and other actors in influencing access to medicines in three East African countries.
Odoch WD; Dambisya Y; Peacocke E; Sandberg KI; Hembre BSH
Health Policy Plan; 2021 Apr; 36(3):312-321. PubMed ID: 33569583
[TBL] [Abstract][Full Text] [Related]
15. [Historical changes in the list of plasma fractionation products placed on the WHO Model List of Essential Medicines].
Sakagami Y; Tsutani K
Yakugaku Zasshi; 2014; 134(2):237-47. PubMed ID: 24369307
[TBL] [Abstract][Full Text] [Related]
16. Essential cancer medicines and cancer outcomes: Cross-sectional study of 124 countries.
Ikpeni OT; Maraj D; Woods H; Workentin A; Booth CM; Persaud N
Cancer Med; 2023 Nov; 12(22):20745-20758. PubMed ID: 37902259
[TBL] [Abstract][Full Text] [Related]
17. Essential tuberculosis medicines and health outcomes in countries with a national essential medicines list.
Maraj D; Steiner L; Persaud N
J Clin Tuberc Other Mycobact Dis; 2022 May; 27():100305. PubMed ID: 35308809
[TBL] [Abstract][Full Text] [Related]
18. Comparison of essential medicines lists in 137 countries.
Persaud N; Jiang M; Shaikh R; Bali A; Oronsaye E; Woods H; Drozdzal G; Rajakulasingam Y; Maraj D; Wadhawan S; Umali N; Wang R; McCall M; Aronson JK; Plüddemann A; Moja L; Magrini N; Heneghan C
Bull World Health Organ; 2019 Jun; 97(6):394-404C. PubMed ID: 31210677
[TBL] [Abstract][Full Text] [Related]
19. Essential cancer medicines in the national lists of countries of the WHO South-East Asia Region: a descriptive assessment.
Chivukula MV; Tisocki K
WHO South East Asia J Public Health; 2018 Sep; 7(2):90-98. PubMed ID: 30136667
[TBL] [Abstract][Full Text] [Related]
20. Bridging the gap? Local production of medicines on the national essential medicine lists of Kenya, Tanzania and Uganda.
Baldeh AO; Millard C; Pollock AM; Brhlikova P
J Pharm Policy Pract; 2023 Jan; 16(1):18. PubMed ID: 36717871
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
